Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis

Minjiang Chen¹, Qiang Li², Yan Xu¹, Jing Zhao¹, Li Zhang¹, Lijuan Wei², Wei Zhong¹† & Mengzhao Wang¹†

¹ Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
² Department of Respiratory, Beijing No.6 Hospital, Beijing, China

Abstract

Background: Real-world evidence of second-line treatment and beyond with immune checkpoint inhibitors (ICIs) in Chinese patients is lacking. Here, we aimed to assess the efficacy, responses, and immune-related side effects of anti-PD-1 agents in real-life practice.

Methods: We retrospectively analyzed consecutive patients who received nivolumab or pembrolizumab monotherapy at Peking Medical College Hospital. We collected baseline characteristics, evaluated treatment efficacy, and categorized immune-related adverse effects (irAEs). Predictive factors of treatment response were also determined.

Results: The study included 97 patients with a median age of 64 years. The majority of patients were male, with nonsquamous histological type and advanced stage tumor, and had a history of smoking. Most patients received ICIs as second-line therapy. Expression of PD-L1 was detected in 34.11% patients. Overall response rate (ORR) and disease control rate (DCR) were 16.49% and 60.82%, respectively. None of the patients achieved complete response (CR). The median PFS and OS were 150 days and 537 days, respectively. The incidence of immune-related toxicities was similar to the one previously reported. Patients with driver gene mutations had shorter PFS than patients without, while patients who encountered irAE had relatively longer PFS.

Conclusions: The real-world clinical outcome of ICIs in second- and further-line NSCLC therapy is promising. Several characteristics may have predictive value for efficacy. Occurrence of irAEs during treatment was acceptable and could be an independent positive predictive for PFS.

Key points

Significant findings of the study

- Efficacy and safety profile of ICIs as second-line treatment or above for patients with NSCLC are promising in real world circumstances
- Incidence and median time to the occurrence of irAEs vary between organs

What this study adds

- Driver gene mutations are associated with lower progression-free survival
- Occurrence of irAEs is associated with higher progression-free survival
Introduction

Advances in immuno-oncology have caused a dramatic shift in the treatment landscape of advanced non-small cell lung cancer (NSCLC) in recent years. Immune checkpoint inhibition therapy, which has a profoundly different cure mechanism from target therapy or chemotherapy, restoring the efficacy of tumor-specific T cells within the tumor microenvironment thereby enhance immune response and has shown promising outcomes in NSCLC. In several clinical trials, immune checkpoint inhibitor (ICI) therapies significantly improved progression-free survival (PFS) compared with chemotherapy. Consequently, the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) approved two PD-1 inhibitors, pembrolizumab and nivolumab, for the first- and second-line treatment of NSCLC.

Although significant responses of NSCLC to PD-1 inhibitors have been demonstrated in clinical trials, there is a paucity of data in real-world. In real-world settings, patient cohorts are more heterogeneous, and some patients are unsuitable for clinical trials. Real-world evidence (RWE) includes data from patients of different background and can help improving management of individual patients. The aim of this study was to assess the efficacy, responses, and immune-related side effects of anti-PD-1 agents in real-life practice after the approval of anti-PD-1 therapy in China. We also analyzed treatment alternatives to PD-1 inhibitors after tumor progression. To our knowledge, this study is the largest single site retrospective study of real-world in China.

Methods

Study design and patient population

This study was conducted in Peking Union Medical College Hospital (PUMCH). Patients were collected from a prospective cohort database (CAPTRA-Lung Study). The inclusion criteria were: (i) pathologically or cytologically diagnosed with advanced or recurrent NSCLC; (ii) progressed after at least first-line treatment with platinum-based doublet chemotherapy; (iii) patients with driver gene mutations also received targeted therapy before initiating immunotherapy; and (iv) treated with second-line monotherapy and beyond of pembrolizumab or nivolumab between 1 April 2017 and 31 December 2019 in PUMCH. Patients’ demographic characteristics, stage of disease at the beginning of therapy, histology, treatment sequence, drug efficacy, survival data, gene mutation profile, and PD-L1 expression of tumor cell using Daco 22C3 antibody were retrieved from the database and subsequently analyzed. All the information was retrospectively collected.

Response and side effect assessment

During the treatment cycles, disease assessments were performed every six weeks. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria v 1.1 were used to evaluate disease responses. Progression-free survival (PFS) was calculated from the beginning of anti-PD-1 treatment to date of progression of disease or death. Overall survival (OS) was calculated from the beginning of anti-PD-1 treatment to death.

Adverse effects (AEs) with an immunological basis were defined immune-related adverse effects (irAEs). All irAEs were classified and graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE; version 5.0).

Statistical analysis

We conducted descriptive analyses on clinical and pathological variables. We compared variables that might be associated with clinical efficacy using univariate and multivariate Cox proportional hazards regression. Progression-free survival (PFS) and overall survival (OS) data are presented as Kaplan-Meier curves. Statistical analyses were performed with SPSS 20 and GraphPad Prism 8.0.

Ethical statement

Every patient in the study had signed their informed consent. The retrospective analysis was approved by the ethic board of PUMCH.

Results

Clinicopathological characteristics of the patients

A total of 2430 patients received treatment at the lung cancer center of PUMCH from 1 April 2017 to 31 December 2019. Among these, 97 patients had received anti-PD-1 treatment as second-line therapy or beyond. The majority of these patients were men (men: women ratio = 2.03:1), and their median age was 64 years.

Most patients had nonsquamous histology type (59.79%) and metastatic disease (77.32%). The most frequent metastatic site was contralateral lung, followed by bone, liver, and adrenal. Most patients had smoking history (58.76%). Checkpoint inhibitor was given a second-line treatment in 72 patients (74.23%) and third or fourth line in 25 patients (25.77%). Nivolumab was given to the majority of patients...
(63.92%). The patients’ characteristics are summarized in Table 1. The treatment choice for each patient is shown in Table S1.

PD-L1 expression and molecular biomarkers had been tested in most patients before initiating the immunotherapy. The tumor cell PD-L1 expressions were assessed in 82 patients. Among these, only 65 patients had enough tumor tissue for the test. PD-L1 expression of tumor cell was >50% in 11 patients (11.34%), ranged between one and 49% in 23 patients (23.71%), and was negative in 31 patients (31.96%) (Table 1). Predictive and prognostic biomarkers including EGFR mutations, ALK fusions, ROS1 fusions, MET-14 skipping, RET rearrangement, and KRAS oncogene had been tested by next generation sequencing or amplification refractory mutation system PCR in 74 patients (including all the nonsquamous NSCLC). The analysis showed that 21 patients had driver gene mutations, including 15 cases (15.46%) of EGFR 19-del or 21-L858R mutations, three cases (3.09%) of ROS1 fusion, two cases (2.06%) of RET rearrangement, and one case (1.03%) of MET-14skipping. KRAS was detected in eight patients (8.25%) (Table 1).

**Immunotherapy-associated toxicity**

None of the 97 patients had known prior history of autoimmune diseases or HIV infection. During anti-PD-1 treatment, four patients had infusion reaction at the first or second cycle, which presented as transient chill and fever. A total of 45 patients (46.39%) experienced irAEs. Of these, 19 patients had irAEs involving more than one organ. The organ most commonly involved was the skin, followed by endocrine system and liver.

The median time from immunotherapy to first irAEs was 63 days. Moreover, the median time to occurrence of irAEs varied between organs and systems (Fig 1). Most irAEs were limited to grade 2, whereas grade 3 or 4 irAEs occurred in nine cases (9.4%). Patients were given systemic glucocorticoids for the treatment of irAEs greater than grade 3, except for endocrine irAEs, for which replacement therapies were given. Cyclosporin A, cyclophosphamide, anti-IL-6 antibody, and anti-TNFα antibody were given to selected patients with critical and refractory diseases. The incidence and grades of irAEs are reported in Table 2.

Nine patients had dose interruptions, and six patients permanently stopped immunotherapy due to myocarditis (two cases), pneumonia (two cases), myocarditis plus pneumonia (one case), and grade 4 bulla (one case). Most patients experienced improvement or resolution of toxicity. Three patients died presumably as a consequence of irAEs. The causes of death were myocarditis, pneumonia, and pneumonia plus myocarditis and hepatitis.

**Response to immunotherapy and follow-up treatments**

The median follow-up time for all patients was 249 days. During this time, 72 patients (74.22%) had disease progression and 42 patients (43.30%) died. The median PFS and OS were 150 days and 537 days, respectively (Fig 2). The estimated rates of OS at six months and 12 months were 76.6% and 58.0%, respectively. Partial responses (PR) were achieved in 16 patients (16.49%). Stable diseases (SD) was achieved in 43 patients (44.33%). None of the patients had complete response (CR). The overall response rate (ORR) and disease control rate (DCR) were 16.93% and 60.82%, respectively.

### Table 1 Characteristics of a cohort of 97 patients with advanced NSCLC

| Variable                           | Total (n) | Percentage (%) |
|------------------------------------|-----------|----------------|
| Age years, median (IQR)            | 64(57–69) |                |
| >65                                | 48        | 49.48          |
| <65                                | 49        | 50.52          |
| Gender                             |           |                |
| Women                              | 32        | 32.99          |
| Men                                | 65        | 67.01          |
| Smoking status                     |           |                |
| History of smoking                 | 57        | 58.76          |
| No history of smoking              | 40        | 41.24          |
| Histology                          |           |                |
| Nonsquamous                        | 58        | 59.79          |
| Squamous                           | 39        | 40.21          |
| Stage at diagnosis                 |           |                |
| IIIb                               | 22        | 22.68          |
| IV                                 | 75        | 77.32          |
| ECOG                               |           |                |
| 0–1                                | 82        | 84.54          |
| ≥2                                 | 15        | 15.46          |
| PD-L1 expression status            |           |                |
| PD-L1 50%                          | 11        | 11.34          |
| PD-L1 1–49%                        | 23        | 23.71          |
| PD-L1 negative                     | 32        | 32.99          |
| Driver mutations                   |           |                |
| Positive                           | 21        | 21.65          |
| Negative                           | 53        | 54.64          |
| Unknown                            | 23        | 23.71          |
| Therapeutic lines                  |           |                |
| Second-line                        | 72        | 74.23          |
| Third-line and above               | 25        | 25.77          |
| History of radiotherapy            |           |                |
| No                                 | 70        | 72.16          |
| Yes                                | 27        | 27.84          |
| ICI drugs                          |           |                |
| Pembrolizumab                      | 35        | 36.08          |
| Nivolumab                          | 62        | 63.92          |
A total of 53 patients received follow-up therapies after progression (54.64%). The regimens included single-drug chemotherapy (23.71%), continued immunotherapy (15.46%), and targeted therapy (15.46%). The most used mono-chemotherapies were docetaxel (12.37%), gemcitabine (4.12%), or paclitaxel (3.09%). Targeted therapies were only used in patients who were positive to driver gene mutations, and consisted of second- or third-generation tyrosine-kinase inhibitors (TKIs) and rechallenge of first-generation TKIs. Eight of the patients who continued immunotherapy had concurrent local treatment such as radiofrequency ablation, localized radiotherapy, and interventional embolotherapy.

**Potential clinical predictors associated with PFS during immunotherapy**

We further investigated the clinicopathological factors that might affect the efficacy of PD-1 inhibitors. Univariate analysis showed that median PFS was significantly increased in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1 who experienced irAEs during therapy (Fig 3). Instead, PFS was significantly shorter in patients with driver gene mutations than in those without (Fig 3). The histology type, selection of different immune drugs, expression of PD-L1, as well as other factors were not associated with PFS. Based on multivariate Cox regression analysis, having driver gene mutations was an independent negative predictive factor while occurrence of irAEs was an independent positive predictive factor of PFS (Table 3).

**Discussion**

Patients with recurrent or advanced NSCLC for whom first-line chemotherapy and/or targeted therapy fail generally have a poor prognosis. ICIs, which have the ability to restore the patient’s antitumor immunity, are becoming the new choice for these patients. In several clinical trials, ICIs have shown a significantly higher response rate and durable clinical response than chemotherapy in patients with advanced NSCLC. Based on the positive results of these clinical trials, ICIs have been approved by both FDA and CFDA for the treatment of advanced NSCLC.

However, most of the evidence to date comes from clinical trials and cannot be generalized to real-world patients. There are only a few retrospective analyses that, however, include smaller cohorts of Chinese patients.

This study retrospectively analyzed the efficacy, outcomes, side effects, and clinical factors associated with

| Events                        | No. of subjects (any grade) | Percentage (%) | No. of subjects (3–4 grade) | Percentage (%) |
|-------------------------------|-----------------------------|----------------|-----------------------------|----------------|
| Cases with irAEs              | 45                          | 46.39          | 9                           | 9.28           |
| Skin                          | 25                          | 25.77          | 3                           | 3.09           |
| Rash                          | 17                          | 17.53          | 2                           | 2.06           |
| Pruritus                      | 5                           | 5.15           | 0                           | 0.00           |
| Bulla                         | 1                           | 1.03           | 1                           | 1.03           |
| Psoriasis                     | 1                           | 1.03           | 0                           | 0              |
| Endocrine                     | 15                          | 15.46          | 3                           | 3.09           |
| Hyperthyroidism               | 8                           | 8.24           | 0                           | 0.00           |
| Hypothyroidism                | 12                          | 12.37          | 0                           | 0.00           |
| Adrenal insufficiency         | 2                           | 2.06           | 2                           | 2.06           |
| Hypopituitarism               | 2                           | 2.06           | 1                           | 1.03           |
| Hepatitis                     | 8                           | 8.24           | 1                           | 1.03           |
| Arthritis                     | 4                           | 4.12           | 0                           | 0.00           |
| Pneumonia                     | 4                           | 4.12           | 3                           | 3.09           |
| Myocarditis                   | 3                           | 3.09           | 3                           | 3.09           |
| Renal†                        | 3                           | 3.06           | 0                           | 0.00           |
| Amylase elevation             | 2                           | 2.06           | 0                           | 0.00           |
| Enteritis and diarrhea        | 2                           | 2.06           | 0                           | 0.00           |
| CK elevation                  | 1                           | 1.03           | 1                           | 1.03           |

†Renal irAE included creatinine elevation and microscopic hematuria.

CK, creatine kinase.
prognosis in a longitudinal cohort of real-world patients with NSCLC receiving monotherapy of ICIs as second-line treatment and above. To the best of our knowledge, this is one of the largest comprehensive retrospective studies of real-world patients from mainland China who were treated with second-line PD-1 inhibitor monotherapy.

In published clinical trials, the ORR of second-line ICI monotherapy ranged from 18 to 37%.

\[ \text{ORR} = \frac{18 \text{ to } 37\%}{} \]

The ORR in our study (16.49%) was comparable to those in previous studies, while the PFS and OS were better than those in clinical trial data (150 and 537 days, respectively).

\[ \text{mPFS} = 150 \text{ days} \]
\[ \text{mOS} = 537 \text{ days} \]

This could be due to several factors. First, clinical response was evaluated by clinicians instead of independent radiology reviewers. This assessment might thus include certain biases, such as tendency to rate the patients as SD instead of PD.

**Figure 2** Kaplan-Meier plot for the 97 patients. (a) Progression-free survival (PFS) and (b) Overall survival (OS) from the beginning of anti-PD-1 treatment (m = median).

**Figure 3** Kaplan-Meier plot for the progression free survival (PFS) stratified by clinical factors. (a) ECOG score; (b) Driver gene mutations; and (c) irAE (m = median).
of progressive disease (PD), and misclassification. Therefore, DCR and PFS rates in this study could be overestimated, compared to those in studies with independent reviewers. Second, characteristics and genetic background of Chinese patients might be different from those of western patients. Third, limited cases and retrospective design of this study might affect the results.

The incidence of total irAEs, ≥ grade 3 irAE, and median time to irAEs in our study were comparable to those in previous reports. The most commonly involved organ was the skin (25.77%), but only a small proportion of skin irAEs (3.09%) were rated above grade 3, and only one case presented grade 4 bulla. All patients recovered after topical or systemic corticosteroids. Most patients continued immunotherapy except for the patient with bulla. The endocrine system was often involved during ICIs therapy, and all affected patients were successfully treated with replacement therapy and symptomatic treatment, and continued immunotherapy afterwards. Carditis and pneumonitis were uncommon (4.12% and 3.09%, respectively). Systemic corticosteroids and immune suppressors were given to patients with severe heart and/or pulmonary irAEs. Most patients experienced severe clinical symptoms and/or laboratory abnormalities and had to halt ICIs permanently. Because of its low incidence and progressive course, and due to limited treatment options, immune-related myocarditis had extremely high mortality. In our study, two patients died of myocarditis after high doses of intravenous glucocorticoids and anti-IL-6 antibody. In previous reports, antithymocyte globulin (ATG) was used in patients with ICI-related severe myocarditis. However, none of the three myocarditis patients received ATG in our study. The incidence of grade 5 irAE was higher than previously reported. It might be because of the limited number of patients. Patients in this study were older and had more comorbidities and poorer performance status than the patients in clinical trials, which have been reported to be factors associated with severe irAEs might also contribute to the relatively high mortality.

Previous studies found that patients with EGFR-sensitive mutations and ALK fusion did not respond well to ICI therapy. Preclinical studies indicate that EGFR mutations activate PD-L1 expression and induce immune escape, although the underlying mechanism is unclear. In real-world settings, cases of EGFR or ALK-mutated patients receiving ICIs are scarce. A retrospective study showed that only one in 28 EGFR-mutant or ALK-positive patients achieved PR as best response. The benefits of ICI therapy on OS in EGFR or ALK-mutated patients were not significant. Recently, a systemic analysis showed no benefit on OS by using second-line nivolumab, pembrolizumab, and atezolizumab treatment in EGFR-mutated patients against docetaxel. In our study, the existence of driver gene mutations was a negative predictive factor of PFS in the future before any conclusion can be drawn.

IrAEs, with an incidence of 40% to 51%, are common side-effects in patients receiving ICIs. Although the underlying mechanism is currently unclear, it appears that irAEs have an intimate link with antitumor effect of ICIs.
In previous studies, patients who developed irAEs had significantly higher ORR as well as longer PFS than patients without. However, patients with severe irAEs who interrupted treatment often had a lower median OS. In our study, the incidence of, and median time to, irAEs were comparable to those in previous studies. The onset of irAEs was shown to be an independent predictive factor for PFS, in agreement with previous studies. Similarly, only a small fraction of patients stopped ICI therapy due to irAEs, which is also consistent with previous studies.

Furthermore, the pattern of follow-up therapies revealed that most patients had further-line therapies, including chemotherapy, and a few patients continued immunotherapy beyond progression. The latter group of patients had oligoprogressive diseases and had been treated with localized therapy along with maintenance ICIs. Although the therapeutic regimen might prolong the PFS2 of driver gene mutated therapy along with maintenance ICIs. Although the efficacy of ICIs in patients resistant to third-line TKIs still needs to be defined. Third, tumor mutation burden, which may affect the efficacy of nivolumab, was not tested in most patients. It would be interesting to collect these data for future studies. Cases from different cancer centers should also be collected and analyzed comprehensively in the future.

In conclusion, in heterogeneous real-world settings, ICI monotherapy showed promising clinical outcomes and acceptable side effects as second- and further-line treatment for patients with advanced NSCLC. Clinical factors such as driver gene mutations and appearance of irAEs were independent predictive factors for PFS. Further prospective studies are required to understand the underlying mechanism and relationship between clinical factors and ICI response in patients.

Acknowledgments

We thank the patients for providing their clinical data for analysis in this study. We acknowledge Lianqing Wang (Beijing No.6 Hospital) for collecting patients’ information.

The study was supported by National Natural Science Foundation of China (Grant No. 81702292) and CAMS Innovation Fund for Medical Sciences (Grant No. 2018-12M-1-003).

Disclosure

The authors declare no potential conflicts of interest.

References

1. Hirsch FR, Suda K, Wiens J, Bunn PA. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet 2016; 388: 1012–24.
2. Reck M, Rodriguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375 (19): 1823–33. https://doi.org/10.1056/NEJMoa1606774.
3. Horn L, Spigel DR, Vokes EE et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35 (35): 3924–33. https://doi.org/10.1200/JCO.2017.74.3062.
4. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387 (10027): 1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.
5. Mok TS, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet 2019; 393 (10183): 1819–30.
6. Gandhi L, Rodriguez-Abreu D, Gadgeli S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018; 378 (22): 2078–92. https://doi.org/10.1056/NEJMoa1801005.
7. Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 2018; 379 (21): 2040–51. https://doi.org/10.1056/NEJMoa1810865.
8. Xu Y, Zhang L, Fang J et al. Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thorac Cancer 2018; 9 (12): 1795–800. https://doi.org/10.1111/1759-7714.12865.
9. Wang C, Thudium KB, Han M et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014; 2 (9): 846–56. https://doi.org/10.1158/2326-6066.CIR-14-0040.
10. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372 (21): 2018–28. https://doi.org/10.1056/NEJMoa1501824.
11. Gauvain C, Vauléon É, Chouaid C et al. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases [published correction appears in Lung Cancer. 2019 Oct; 136: 159]. Lung Cancer 2018; 116: 62–6. https://doi.org/10.1016/j.lungcan.2017.12.008.
12 Lin SY, Yang CY, Liao BC et al. Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan. J Cancer 2018; 9 (10): 1813–20. https://doi.org/10.7150/jca.24985.

13 Song P, Zhang J, Shang C, Zhang L. Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Sci Rep 2019; 9 (1): 4278. https://doi.org/10.1038/s41598-019-40748-7.

14 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015; 373 (2): 123–35. https://doi.org/10.1056/NEJMoa1504627.

15 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373 (17): 1627–39. https://doi.org/10.1056/NEJMoa1507643.

16 Morita R, Okishio K, Shimizu J et al. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan. Lung Cancer 2020; 140: 8–18. https://doi.org/10.1016/j.lungcan.2019.11.014.

17 Jain V, Mohebtash M, Rodrigo ME, Ruiz G, Atkins MB, Barac A. Autoimmune myocarditis caused by immune checkpoint inhibitors treated with antithymocyte globulin. J Immunother 2018; 41 (7): 323–5. https://doi.org/10.1097/JIM.0b013e3182745948.

18 Wang Y, Zhou S, Yang F et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol 2019; 5 (7): 1008–19. https://doi.org/10.1001/jamaoncol.2019.0393.

19 Baldini C, Martin Romano P, Voisin AL et al. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Eur J Cancer 2020; 129: 71–9. https://doi.org/10.1016/j.ejca.2020.01.013.

20 Akbay EA, Koyama S, Carretero J et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov 2013; 3 (12): 1355–63. https://doi.org/10.1158/2159-8290.CD-13-0310.

21 Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin Cancer Res 2016; 22 (18): 4585–93. https://doi.org/10.1158/1078-0432.CCR-15-3101.

22 Lee CK, Man J, Lord S et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer: A meta-analysis. J Thorac Oncol 2017; 12 (2): 403–7. https://doi.org/10.1016/j.jtho.2016.10.007.

23 Toi Y, Sugawara S, Kawashima Y et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist 2018; 23 (11): 1358–65. https://doi.org/10.1634/theoncologist.2017-0384.

24 Haratani K, Hayashi H, Chiba Y et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol 2018; 4 (3): 374–8. https://doi.org/10.1001/jamaoncol.2017.2925.

25 Sato K, Akamatsu H, Murakami E et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab [published correction appears in Lung Cancer 2018 Dec; 126: 230–231]. Lung Cancer 2018; 115: 71–4. https://doi.org/10.1016/j.lungcan.2017.11.019.

26 Ksienzki D, Wai ES, Croteau N et al. Efficacy of nivolumab and pembrolizumab in patients with advanced non-small-cell lung cancer needing treatment interruption because of adverse events: A retrospective multicenter analysis. Clin Lung Cancer 2019; 20 (1): e97–e106. https://doi.org/10.1016/j.cllc.2018.09.005.

27 Weichhardt AJ, Scheier B, Burke JM et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012; 7 (12): 1807–14. https://doi.org/10.1097/JTO.0b013e3182745948.

28 Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis 2018; 10 (Suppl 21): S2537–44. https://doi.org/10.21037/jtd.2018.07.19.

Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website.

Table S1 The treatment choice of all the 97 patients.